The company forecasts $5 billion in COVID vaccine ... our list price—when we have our updated vaccines—to be in the range of $110 to $130," Garay said. In March, Moderna CEO Stéphane Bancel ...
Moderna maintained its full-year guidance of a minimum of $5 billion in revenue from its Covid vaccine, which will come from signed government contracts for the shot. CEO Stéphane Bancel said ...
Pfizer and Moderna say their work on their blockbuster Covid vaccines is ... length of the mRNA strand in the vaccine, according to Burton. The shot could increase the number of vaccine ...
Biotech company Alnylam Pharmaceuticals Inc filed new lawsuits on Friday against Pfizer Inc and Moderna Inc in Delaware ...
Moderna hits roadblock in flu Moderna CEO defends Covid vaccine price hike in Senate grilling Related: Moderna CEO defends Covid vaccine price hike in Senate grilling ...
The logistics involved will become more costly and complex than when Moderna was selling directly to national governments. But the company plans on increasing the price of its vaccine to as much ...
Meanwhile, Amazon CEO Andy ... Sanders spoke out against Moderna's "corporate greed" in a March hearing over the company possibly quadruple the price of the COVID-19 vaccine.
The company did not change its forecast of $5 billion in COVID vaccine sales for the year based on advance purchase agreements. But Moderna said it was in discussions about new contracts with ...
Moderna (NASDAQ ... Decline 20% In December? Vaccine specialist Novavax (NASDAQ: NVAX) - which is seen as a key player in the Covid-19 vaccine space - saw its stock price decline by about 20% ...
The key metric for Moderna will continue to be Covid-19 vaccine revenue, which has been declining since the fourth quarter of 2021. The company posted $6.93 billion in vaccine revenue in that ...
Protesters gathered Wednesday afternoon outside the Beacon Hill home of the Moderna CEO Stéphane Bancel, calling on the company to make the technology behind its COVID-19 vaccine ... capacity to ...
(Reuters) - Moderna Inc on Thursday reported a small profit of 19 cents per share instead of an expected loss as it booked more revenue in the first quarter from last year's deferred orders for its ...
